All News
ACR 2022 - Day 1 Report
The masses have returned to ACR22, a live, face-to-face, and virtual, meeting that began Saturday in Philadelphia. There were hassles and glitches, yet the education and sessions were as you’d expect with many good presentations worth recapping.
Read Article
ACR Best Abstracts - Day 1
The RheumNow faculty reporters have been scouring the meeting and online presentations to find the best abstracts from ACR22. Here are some of their choice abstracts reported today on day 1 of ACR 2022 (#ACRbest).
Read Article
Adding MTX to Pegloticase for 52 wks in gout
◦ Improved response rate by 30%
◦ Reduced discontinuation rate by 40%
◦ Greater resolution of tophi by 20%
◦ Similar safety profile in MTX vs non-MTX groups
Botson J, MIRROR RCT https://t.co/ifXLdvOv0K #ACR22 #ACRBest @RheumNow https://t.co/le9ggUa2Xk
Dr. Antoni Chan synovialjoints ( View Tweet)
This work can lay foundation to so much more!
#ArtificialIntelligence and #naturallanguageprocessing on Facebook private #gout groups
- Mental health mentioned in 4% of all posts/comments
- primary care asso with “trust” and urgent care with “fear”
@RheumNow #ACR22 abst#0201 https://t.co/fSuOeNGWvg
Bella Mehta bella_mehta ( View Tweet)
Botson et al. 52 week results MIRROR trial. MTX added to pegloticase. 71% vs 39% SU <6mg/dl. Infusion reaction 13% vs 32% if ab+ 0% vs 30% ab- @RheumNow #ACR22 Abstr#0001 #ACRbest https://t.co/1c3Va9NxNX https://t.co/dPGDyWue4G
Richard Conway RichardPAConway ( View Tweet)
Black study subjects remain underrepresented in rheumatology clinical trials except for gout. Abs 0089
Continued under-reporting of race and ethnicity in PsA trials. Abs 0090
We can do better #rheumtwitter
#ACR22 @RheumNow https://t.co/lzFXxFxgNs and https://t.co/K9dYaaXCg8 https://t.co/VqQe1OCsKg
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
#ACR22 Plenary 1. Abstr#0001 Another important use of #methotrexate. MIRROR RCT showed greater response in pegloticase + MTX vs pegloticase + PBO and lower infusion reaction. Be interesting to define MTX dose and ?other DMARDs esp in patients with CKD @RheumNow #ACRBest https://t.co/xkP6ZZGQfu
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Abst#0001 MIRROR RCT at #ACR22 #plenary
Pts with gout on #pegloticase and #gout
sustained higher urate lowering response in pts cotreated with #MTX
benefit beyond 6 months
@rheumnow https://t.co/rTZ3fPaFJS
Bella Mehta bella_mehta ( View Tweet)
🪞MIRROR RCT🪞
💊MTX ⬆️ response of Pegloticase in resistant gout pts (60% vs PBO 30.8%)
🦶Tophus resolution wk 52 >24 (cont. benefit💪🏻)
🧪⬇️ drug Ab with MTX
✅ No new IRs
Abst#0001 #ACR22 @RheumNow #plenary https://t.co/8lPKQ0VGqC
Patricia Harkins DrTrishHarkins ( View Tweet)
Excellent start to the first plenary session!
MIRROR study - MTX coadministration with pegloticase for gout treatment
- doubling of efficacy and 7x decrease in infusion reactions
- less anti-PEG abs
@RheumNow #ACR22 Abs#0001 https://t.co/V1HIYypmpO
Robert B Chao, MD doctorRBC ( View Tweet)
MIRROR results showed 12-month safety/efficacy support MTX co-therapy w/ pegloticase. No IRs after 6mo of tx and increased resolution of tophi at wk 52. I use MTX in my gout pts on Pegloticase. Are you #rheumtwitter? Abs 0001 #ACR22 @RheumNow https://t.co/FLwOmAYrS4
Dr. Rachel Tate uptoTate ( View Tweet)
Role of acquired mutations in #gout
Risk factor for gout CHIP?
Individuals with CHIP are more likely to developed acute episodes of gouty episodes
More IL-1B in cells with somatic mutations like CHIP
@rheumnow #ACR22 #yearinreview https://t.co/k3VeZuTCln
Bella Mehta bella_mehta ( View Tweet)
CHIP- need to know! Somatic mutations fondly known as CHIP - not the salty ones. Clonal hematopoeisis of uncertain significance. Older Pts getting somatic mutations account for more CVS, malignancies , one change in TET2 increased gout #ACR2022 @RheumNow John Barga Yr in Review https://t.co/6bnqnkDFpL
Janet Pope Janetbirdope ( View Tweet)
MTX increases pegloticase efficacy in MIRROR trial. Similar safety too. Shame the cost of pegloticase is prohibitive in Australia...
@RheumNow #ACR22 #yearinreview
Julian Segan JulianSegan ( View Tweet)
Year in Review
#ACR22
Pegloticase and MTX now FDA approved co-administration for tophaceous gout to prevent anti-drug antibodies
@RheumNow https://t.co/EPtOrjJqLd
Eric Dein ericdeinmd ( View Tweet)
Preview of what is sure to be discussed more in detail later..
MIRROR trial of MTX co-administration with pegloticase in treatment of gout.
MTX co-administration improved control of gout, reduced infusion reactions
@RheumNow #ACR22 https://t.co/r0MEq1rkgO
Robert B Chao, MD doctorRBC ( View Tweet)
Population study shows among vaccinated gout pts, COVID breakthrough infection occurred in @ 4.68/1K Pt-mos vs 3.76/1K Pt-mos in non-Gout persons. Gout w/ Covid had More Hosp (aHR=1.30) & death (aHR=1.36), moreso in Women w/ gout (aHR 1.55 & 2.46) https://t.co/ViwiPzqTbZ https://t.co/BrXd6pbgRI
Links:
Dr. John Cush RheumNow ( View Tweet)
Single center study from UAB shows 72 gout pts treated & D/C from ED were Rx w/ steroids (64%), opioids (63%), NSAIDs (43%), colchicine (32%). But only 26/72 (36%) had subsequent outpatient clinic visit for gout. https://t.co/I8jjqIqJXd https://t.co/05YSibd6iz
Links:
Dr. John Cush RheumNow ( View Tweet)
Will we see you there? #ACR2022
What are you most looking forward to on the agenda? https://t.co/KQGHJtwboe
Dr. John Cush RheumNow ( View Tweet)
#Gout clinic study of 223 gout pts on allopurinol ≥300 mg compared Pt & MD gout control assessments (0-10). Better agreement & higher scores seen w/o flares (3 or 12 mos) & SUA w/in target. Disagreement (22%) w/ recent flares & tophi https://t.co/a0WsMLvfYk https://t.co/zZwV4XVJzS
Links:
Dr. John Cush RheumNow ( View Tweet)
